Fragment 176-191
Also known as: GH Fragment 176-191, HGH Frag 176-191, AOD-9401
Overview
Fragment 176-191 refers to the unmodified C-terminal peptide fragment of human growth hormone spanning amino acids 176-191. It is the precursor compound from which AOD-9604 was developed via a stabilizing tyrosine modification. Research suggests antilipogenic activity primarily through inhibition of fat formation rather than direct lipolysis stimulation, representing a slightly different activity profile than AOD-9604.
Mechanism of Action
Similar to AOD-9604 but without the tyrosine modification. In vitro rat adipose tissue studies demonstrate antilipogenic activity—reduction in fat storage enzyme activity—with less direct lipolytic activity than the full GH molecule or AOD-9604. Mechanistically interacts with beta-adrenergic pathways in adipose tissue and does not activate GH receptors or stimulate IGF-1.
Potential Benefits
- Antilipogenic properties in preclinical adipose models
- No growth-promoting or IGF-1 stimulating effects
- Potential body composition improvement
- Selective targeting of fat metabolism without systemic GH effects
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Research compound only. Rodent studies use 500 mcg/kg. No established human dosing.
Amino Acid Sequence
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Side Effects & Safety
- Limited human safety data
- Injection site reactions
- Theoretical endocrine effects
Synergistic Compounds
The following compounds have been studied alongside Fragment 176-191 for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]